IMJUDO 20 MG
TREMELIMUMAB : 20 MG · DIN 02541009 · ASTRAZENECA CANADA INC
Health Canada status: MARKETED
What is IMJUDO?
IMJUDO 20 MG contains TREMELIMUMAB : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02541009, held by ASTRAZENECA CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Oct-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMJUDO used for?
In combination with durvalumab for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02541009 |
|---|---|
| Brand name | IMJUDO |
| Generic / active ingredient | TREMELIMUMAB : 20 MG |
| Manufacturer | ASTRAZENECA CANADA INC |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FX20 TREMELIMUMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Oct-2023 |
How is it administered?
300 mg as a single dose, followed by durvalumab 1500 mg at Day 1 of Cycle 1. Administer via IV infusion over 60 minutes. Weight-based dosing for patients ≤ 30 kg.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in a refrigerator (2°C to 8°C). Do not freeze. Store in original package to protect from light.
How is it supplied?
1.25 mL (25 mg) or 15 mL (300 mg) concentrate in a Type I glass vial. Pack size of 1 single-dose vial.
Contraindications
Hypersensitivity to tremelimumab or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Can cause severe and fatal immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, rash, myocarditis, etc.). Monitor patients continuously.
Who else supplies TREMELIMUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TREMELIMUMAB appears in 13 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.